<?xml version="1.0" encoding="UTF-8"?>
<iati-activities version="2.03">
 <iati-activity default-currency="EUR" hierarchy="1" iati-activities:version="2.03" xml:lang="EN" xmlns:iati-activities="http://d-portal.org/xmlns/iati-activities" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="http://iatistandard.org/203/schema/downloads/iati-activities-schema.xsd">
  <iati-identifier>NL-KVK-41207989-P-22605-2S4KN</iati-identifier>
  <reporting-org ref="NL-KVK-41207989" type="21">
   <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
  </reporting-org>
  <title>
   <narrative xml:lang="EN">A novel approach to cure HIV-1</narrative>
  </title>
  <description type="4">
   <narrative xml:lang="EN">Although current antiretroviral therapy (ART) reduces viral loads to undetectable levels in the circulation, HIV quickly resumes active replication when treatment is interrupted, due to the emergence of the replication-competent virus from latent reservoirs. Therefore, HIV-1 infected individuals face life-long ART, unless a functional or sterilizing cure is developed. This program will evaluate the potential of the CRISPR/Cas9 technology to achieve a sterilizing cure by permanently inactivating the virus in already-infected cells.</narrative>
  </description>
  <description type="1">
   <narrative xml:lang="EN">Current drug therapies against HIV effectively suppress the virus, but do not cure the virus infection. The virus persists in latent reservoirs in the human body and rebounds when drug treatment is interrupted. We will investigate a novel anti-HIV approach that is based on a recently developed gene-editing technique (CRISPR-Cas9). The aim is to remove or permanently inactivate all the virus genomes that are present in infected cells, which would in principle constitute a cure for HIV.</narrative>
  </description>
  <description type="3">
   <narrative xml:lang="EN">Eventually, all HIV-1 infected individuals. Initially, those with drug-resistant HIV-1 variants and those that have difficulties to comply with ART.</narrative>
  </description>
  <description type="2">
   <narrative xml:lang="EN">In principal, elimination or permanent inactivation of the proviral DNA in every infected cell will cure HIV-1 infection. Therefore, the end-goal of the research line will be a novel gene therapy for HIV-1 infected individuals that aims to remove HIV-1 from infected cells or permanently inactivate HIV-1 in infected cells, thus curing HIV-1 infected individuals.</narrative>
  </description>
  <participating-org ref="NL-KVK-41207989" role="1" type="22">
   <narrative xml:lang="EN">Aidsfonds Grants</narrative>
  </participating-org>
  <participating-org ref="NL-KVK-41207989" role="2" type="22">
   <narrative xml:lang="EN">Aidsfonds</narrative>
  </participating-org>
  <activity-status code="4"></activity-status>
  <activity-date iso-date="2018-02-01" type="1"></activity-date>
  <activity-date iso-date="2019-04-01" type="3"></activity-date>
  <contact-info type="1">
   <organisation>
    <narrative xml:lang="EN">Aidsfonds - Soaaids Nederland</narrative>
   </organisation>
   <telephone>+31(0)206262669</telephone>
   <email>IATI@aidsfonds.nl</email>
  </contact-info>
  <recipient-country code="NL" percentage="100"></recipient-country>
  <location>
   <name>
    <narrative xml:lang="EN">Amsterdam</narrative>
   </name>
  </location>
  <sector code="13040" percentage="100" vocabulary="1">
   <narrative xml:lang="EN">A novel approach to cure HIV-1 STD control including HIV/AIDS</narrative>
  </sector>
  <policy-marker code="9" significance="1" vocabulary="1"></policy-marker>
  <collaboration-type code="3"></collaboration-type>
  <default-flow-type code="30"></default-flow-type>
  <default-finance-type code="110"></default-finance-type>
  <default-aid-type code="C01" vocabulary="1"></default-aid-type>
  <default-tied-status code="5"></default-tied-status>
  <budget status="1" type="1">
   <period-start iso-date="2018-02-01"></period-start>
   <period-end iso-date="2019-04-01"></period-end>
   <value currency="EUR" value-date="2018-02-01">75000</value>
  </budget>
  <transaction>
   <transaction-type code="11"></transaction-type>
   <transaction-date iso-date="2017-10-26"></transaction-date>
   <value currency="EUR" value-date="2017-10-26">75000</value>
   <provider-org provider-activity-id="NL-KVK-41207989-" ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2020-01-28"></transaction-date>
   <value currency="EUR" value-date="2020-01-28">7500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org ref="NL-KVK-34362777">
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2017-10-26"></transaction-date>
   <value currency="EUR" value-date="2017-10-26">67500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="3"></transaction-type>
   <transaction-date iso-date="2017-10-26"></transaction-date>
   <value currency="EUR" value-date="2017-10-26">67500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
  <transaction>
   <transaction-type code="2"></transaction-type>
   <transaction-date iso-date="2020-01-28"></transaction-date>
   <value currency="EUR" value-date="2020-01-28">7500</value>
   <provider-org ref="NL-KVK-41207989">
    <narrative xml:lang="EN">Aidsfonds Grants</narrative>
   </provider-org>
   <receiver-org>
    <narrative xml:lang="EN">AMC - Laboratory of Experimental Virology</narrative>
   </receiver-org>
  </transaction>
 </iati-activity>
</iati-activities>
